or Try an Advanced Search...

    Technical Analysis for VTYX - Ventyx Biosciences, Inc.

    Grade Last Price % Change Price Change
    F 2.26 -2.16% -0.05
    VTYX closed down 2.16 percent on Monday, July 1, 2024, on 81 percent of normal volume. The price action carved out a bullish hammer (or hammer-like) candlestick pattern. That may indicate an upside reversal. Look for price to trade above the high of the hammer for confirmation. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
    2 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Strong Down Down Down
    Historical VTYX trend table...
    Date Alert Name Type % Chg
    New Downtrend Bearish 0.00%
    Hammer Candlestick Bullish 0.00%
    Narrow Range Bar Range Contraction 0.00%
    Wide Bands Range Expansion 0.00%
    Oversold Stochastic Weakness 0.00%
    Narrow Range Bar Range Contraction -2.16%
    Wide Bands Range Expansion -2.16%
    Oversold Stochastic Weakness -2.16%
    Bullish Engulfing Bullish -5.44%
    Narrow Range Bar Range Contraction -5.44%
    Older End-of-Day Signals for VTYX ...

       Recent Intraday Alerts

    Alert Time
    Down 5% about 8 hours ago
    60 Minute Opening Range Breakdown about 8 hours ago
    Down 3% about 10 hours ago
    Fell Below Previous Day's Low about 10 hours ago
    Down 2 % about 10 hours ago
    View Earlier Intraday Alerts

    Get a Trading Assistant

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Get Started for Free!
    Configure default chart indicators
    VTYX Chart by TradingView
    Basic chart:

    Profile

    Ventyx Biosciences, Inc. Description

    Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates for inflammatory diseases and autoimmune disorders. The company's lead product candidate is VTX958, a tyrosine kinase type 2 inhibitor that is in phase I clinical trials for the treatment of immune-mediated diseases, such as psoriasis, inflammatory bowel disease, psoriatic arthritis, and lupus. It also develops VTX002, an oral sphingosine 1 phosphate receptor 1 modulator that has completed phase I clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral-targeted NOD-like receptor protein 3 (NLRP3) inflammasome inhibitor for the treatment of systemic inflammatory diseases, such as cardiovascular, hepatic, renal, and rheumatologic diseases. In addition, the company develops CNS-penetrant NLRP3 inhibitors. Ventyx Biosciences, Inc. was incorporated in 2018 and is based in Encinitas, California.

    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Biopharmaceutical Clinical Medicine Autoimmune Disease Inflammatory Diseases Psoriasis Inflammatory Bowel Disease Ulcerative Colitis Autoimmune Disorders Cytokine Lupus Immune Mediated Diseases Molecule Product Psoriatic Arthritis Inflammasome

    Is VTYX a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Jul 1 Ventyx Biosciences: Slim Chances In A Fat Market (Rating Downgrade)
    Jun 5 Ventyx reports preclinical results for anti-obesity drug VTX3232
    Jun 5 Ventyx Biosciences Announces Positive Preclinical Data for CNS-Penetrant NLRP3 Inhibitor VTX3232 Demonstrating Reversal of Obesity and Improvements in Cardiometabolic and Inflammatory Markers
    May 16 Ventyx Biosciences to Participate in Three Upcoming Investor Conferences
    May 16 Ventyx Biosciences gets new operations chief
    May 16 Ventyx Biosciences Announces Appointment of Matthew Moore as Chief Operating Officer
    May 13 Ventyx Biosciences, Inc. (NASDAQ:VTYX) Q1 2024 Earnings Call Transcript
    May 11 Ventyx Biosciences, Inc. (VTYX) Q1 2024 Earnings Call Transcript
    May 9 Ventyx Biosciences GAAP EPS of -$0.62 beats by $0.05
    May 9 Ventyx Biosciences Reports First Quarter 2024 Financial Results and Highlights Recent Corporate Progress
    See more VTYX news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 40.42
    52 Week Low 1.865
    Average Volume 1,085,082
    200-Day Moving Average 7.83
    50-Day Moving Average 3.93
    20-Day Moving Average 3.09
    10-Day Moving Average 2.47
    Average True Range 0.32
    RSI (14) 27.01
    ADX 25.54
    +DI 13.77
    -DI 30.08
    Chandelier Exit (Long, 3 ATRs) 4.71
    Chandelier Exit (Short, 3 ATRs) 3.13
    Upper Bollinger Bands 4.89
    Lower Bollinger Band 1.29
    Percent B (%b) 0.27
    BandWidth 116.33
    MACD Line -0.56
    MACD Signal Line -0.53
    MACD Histogram -0.0316
    Fundamentals Value
    Market Cap 133.45 Million
    Num Shares 59 Million
    EPS -3.15
    Price-to-Earnings (P/E) Ratio -0.72
    Price-to-Sales 0.00
    Price-to-Book 0.49
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 2.46
    Resistance 3 (R3) 2.46 2.38 2.43
    Resistance 2 (R2) 2.38 2.33 2.39 2.42
    Resistance 1 (R1) 2.32 2.30 2.29 2.33 2.41
    Pivot Point 2.25 2.25 2.23 2.25 2.25
    Support 1 (S1) 2.19 2.20 2.15 2.19 2.11
    Support 2 (S2) 2.11 2.16 2.12 2.10
    Support 3 (S3) 2.05 2.11 2.09
    Support 4 (S4) 2.06